ANAVEX LIFE SCIENCES CORP. - COMMON STOCK

Anavex Life Sciences to Present at the BTIG Virtual Biotechnology Conference 2023

02 Aug 2023 06:30:00 By Nasdaq GlobeNewswire

Anavex Life Sciences to Announce Fiscal 2023 Third Quarter Financial Results on Tuesday August 8, 2023

01 Aug 2023 06:30:01 By Nasdaq GlobeNewswire

Long-term Clinical Study Demonstrates Disease Modifying Effects of ANAVEX®2-73 (blarcamesine) for Rett Syndrome

28 Jun 2023 06:30:00 By Nasdaq GlobeNewswire

Anavex Life Sciences and Partex Group Announce Strategic Partnership to Leverage AI for Drug Development and Healthcare Sales Marketing Building a Patient-Centric Digital Ecosystem

27 Jun 2023 06:30:00 By Nasdaq GlobeNewswire

Anavex Life Sciences to Present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference

20 Jun 2023 06:30:00 By Nasdaq GlobeNewswire

ANAVEX®2-73 (blarcamesine) Receives Compassionate Use Authorization for Pediatric Patients with Rett Syndrome

15 Jun 2023 06:30:00 By Nasdaq GlobeNewswire

Anavex Life Sciences Reports Publication in Medical Journal Signifying Continued Commitment for Improvement of the Rett Syndrome Caregiver Outcome Measure RSBQ

12 Jun 2023 06:30:00 By Nasdaq GlobeNewswire

Anavex Life Sciences Announces Completion of ANAVEX(®)2-73 (blarcamesine) EXCELLENCE Phase 2/3 Rett Syndrome Clinical Trial

06 Jun 2023 06:30:00 By Nasdaq GlobeNewswire

ANAVEX Announces Issuance of New U.S. Intellectual Property Compositions Patent for ANAVEX®2-73 (blarcamesine)

01 Jun 2023 06:30:00 By Nasdaq GlobeNewswire

Anavex Life Sciences Reports Fiscal 2023 Second Quarter Financial Results

09 May 2023 06:30:01 By Nasdaq GlobeNewswire

Anavex Life Sciences to Announce Fiscal 2023 Second Quarter Financial Results on Tuesday, May 9, 2023

02 May 2023 06:30:00 By Nasdaq GlobeNewswire

Anavex Life Sciences Announces Issuance of New U.S. Patent Expanding ANAVEX®2-73 (blarcamesine) Intellectual Property Portfolio for the Treatment of Hypertension

01 May 2023 06:30:00 By Nasdaq GlobeNewswire

Anavex Life Sciences to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ

25 Apr 2023 06:30:00 By Nasdaq GlobeNewswire

Anavex Life Sciences to Present at the 22nd Annual Needham Virtual Healthcare Conference 2023

10 Apr 2023 06:00:00 By Nasdaq GlobeNewswire

ANAVEX®2-73 (Blarcamesine) Shows Clinical Benefit in Long-Term 48-Week Phase 2 Extension Study in Patients with Parkinson’s Disease Dementia

30 Mar 2023 06:00:00 By Nasdaq GlobeNewswire

Anavex Life Sciences Appoints Former FDA Lead Neurology Statistician as Vice President Head of Biostatistics

09 Mar 2023 06:00:00 By Nasdaq GlobeNewswire

Anavex Life Sciences Reports Fiscal 2023 First Quarter Financial Results

07 Feb 2023 06:00:01 By Nasdaq GlobeNewswire

Anavex Life Sciences Announces Exceeding of Enrollment Target for the ANAVEX®2-73 (blarcamesine) EXCELLENCE Phase 2/3 Rett Syndrome Clinical Trial

02 Feb 2023 06:00:00 By Nasdaq GlobeNewswire

Anavex Life Sciences to Announce Fiscal 2023 First Quarter Financial Results on Tuesday February 7, 2023

31 Jan 2023 06:00:01 By Nasdaq GlobeNewswire

Anavex Strengthens Scientific Advisory Board with Investigator from Phase 2b/3 Alzheimer’s Trial

14 Dec 2022 06:00:01 By Nasdaq GlobeNewswire